Study guide
14.1 Acute Kidney Injury & Chronic Kidney Disease
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease
Key Takeaways Explain This Topic AI
KDIGO defines AKI Stage 1 (creatinine 1.5–1.9x baseline or >=26.5 umol/L rise; urine output <0.5 mL/kg/h for 6–12h), Stage 2 (creatinine 2.0–2.9x baseline; UO <0.5 mL/kg/h for >=12h), and Stage 3 (creatinine >=3.0x baseline or >=353 umol/L or RRT initiation; UO <0.3 mL/kg/h for >=24h or anuria for >=12h).
Prerenal uraemia is differentiated from intrinsic acute tubular necrosis (ATN) by fractional excretion of sodium (FeNa <1% vs >2%), urine osmolality (>500 vs <350 mOsm/kg), and urine microscopy (bland hyaline casts vs muddy brown granular casts); in patients receiving loop diuretics, fractional excretion of urea (FeUrea <35% vs >50%) provides superior diagnostic accuracy.
Refractory metabolic acidosis (pH <7.20), refractory hyperkalaemia (>6.5 mmol/L), dialysable toxins (salicylates, lithium, isopropanol, methanol, ethylene glycol), refractory pulmonary oedema, and uraemic complications (pericarditis, encephalopathy) represent emergency indications for renal replacement therapy.
KDIGO stratifies CKD by both eGFR (G1 >=90 to G5 <15 mL/min/1.73m2) and albuminuria (A1 ACR <3 mg/mmol, A2 ACR 3–30 mg/mmol, A3 ACR >30 mg/mmol); blood pressure targets are <130/80 mmHg if ACR >=30 mg/mmol, with first-line renoprotection provided by ACE inhibitors or ARBs, SGLT2 inhibitors, and non-steroidal MRAs (finerenone).
Anaemia of CKD requires correction of absolute or functional iron deficiency (ferritin >100 ug/L and transferrin saturation >20%) prior to initiating erythropoiesis-stimulating agents, with a strict target haemoglobin of 100–115 g/L to avoid excess cardiovascular mortality.
Last updated: September 2026
Renal medicine forms a high-yield component of the MRCP(UK) Part 1 examination. Mastery of acute kidney injury (AKI) staging, the physiological discrimination between prerenal and intrinsic renal failure, emergency indications for renal replacement therapy (RRT), and the multimodal management of chronic kidney disease (CKD) and its mineral-bone complications is clinically vital and frequently examined.
1. Acute Kidney Injury: KDIGO Classification & Staging
Acute kidney injury is defined by the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines as any of the following:
An increase in serum creatinine by >= 26.5 µmol/L (>= 0.3 mg/dL) within 48 hours; OR
An increase in serum creatinine to >= 1.5x baseline, known or presumed to have occurred within the prior 7 days; OR
Urine volume < 0.5 mL/kg/h for 6 consecutive hours.
KDIGO stages AKI according to the severity of biochemical and oliguric derangement, with staging determined by the parameter representing the worse degree of insult.
- KDIGO Stage Serum Creatinine Criteria Urine Output Criteria
- Stage 1 1.5–1.9x baseline OR increase >= 26.5 µmol/L within 48h < 0.5 mL/kg/h for 6–12 hours
- Stage 2 2.0–2.9x baseline < 0.5 mL/kg/h for >= 12 hours
Stage 3 3.0x baseline OR serum creatinine >= 353 µmol/L (4.0 mg/dL) OR initiation of renal replacement therapy OR in patients < 18 years, decrease in eGFR to < 35 mL/min/1.73 m² < 0.3 mL/kg/h for >= 24 hours OR anuria for >= 12 hours
Baseline Creatinine Pearl: When a pre-admission creatinine is unavailable, UK guidelines recommend using the lowest creatinine recorded within the preceding 3 months (or up to 12 months). If completely absent, a baseline value can be back-calculated using the MDRD or CKD-EPI formula assuming an average normal eGFR of 75 mL/min/1.73 m².
2. Prerenal AKI vs. Acute Tubular Necrosis (ATN) vs. Postrenal AKI
Distinguishing transient renal hypoperfusion ( prerenal uraemia ) from established parenchymal damage ( acute tubular necrosis ) is essential for guiding fluid therapy versus volume restriction.
Pathophysiological Distinction
Prerenal AKI: Renal parenchymal integrity is intact. Systemic hypovolaemia, cardiogenic shock, sepsis-induced vasodilation, or renal autoregulatory failure (e.g. concurrent NSAIDs constricting afferent arterioles and ACEi/ARBs dilating efferent arterioles) decreases glomerular hydrostatic pressure. Intact proximal and collecting tubules avidly reabsorb sodium and water under intense angiotensin II and aldosterone stimulation, generating concentrated, sodium-poor urine.
Intrinsic ATN: Ischaemic or nephrotoxic injury causes swelling, sloughing, and necrosis of renal tubular epithelial cells (particularly in the metabolically vulnerable straight S3 segment of the proximal tubule and medullary thick ascending limb). Loss of tubular epithelial cell polarity, brush-border detachment, cast obstruction, and transtubular backleak of glomerular filtrate impair the ability of the kidney to concentrate urine or conserve sodium, producing isotonic, sodium-rich urine.
Postrenal AKI: Mechanical obstruction of urinary outflow (prostatic hypertrophy, retroperitoneal fibrosis, pelvic malignancy, bilateral ureteric calculi). Intraluminal pressure rises retrograde into Bowman's space, opposing glomerular filtration. Renal ultrasonography demonstrates pelvicalyceal dilation ( hydronephrosis ). Catheterisation or urgent percutaneous nephrostomy/ureteric stenting is diagnostic and therapeutic. Beware false-negative ultrasound in the hyperacute phase (< 24 hours) or in retroperitoneal fibrosis (which encases and prevents ureteric dilation).
Diagnostic Parameter Prerenal Uraemia Intrinsic ATN Clinical Mechanism / Diagnostic Caveat
Fractional Excretion of Sodium (FeNa) < 1% > 2% FeNa = (Urine Na × Serum Cr) / (Serum Na × Urine Cr) × 100. ATN loses ability to reabsorb sodium.
Fractional Excretion of Urea (FeUrea) < 35% > 50% Mandatory test if on loop/thiazide diuretics , as diuretics cause natriuresis and falsely elevate FeNa above 1%. Urea reabsorption in the proximal tubule remains intact during prerenal hypoperfusion.
Urinary Sodium Concentration < 20 mmol/L > 40 mmol/L Avid aldosterone-mediated distal sodium conservation in prerenal state.
Urine Osmolality > 500 mOsm/kg < 350 mOsm/kg Hyperosmolar medullary gradient and ADH action intact in prerenal; loss of tubular concentrating ability (isosthenuria) in ATN.
Urine/Plasma Creatinine Ratio > 40:1 < 20:1 Concentrated tubular filtrate in prerenal; failure to reabsorb water in ATN.
Serum Urea/Creatinine Ratio > 100:1 (molar ratio) < 40:1 (molar ratio) Enhanced proximal tubular reabsorption of urea alongside water in low-flow states.
Urine Microscopy Bland sediment; normal or hyaline casts Muddy brown granular casts , renal tubular epithelial cells Granular casts represent aggregated Tamm-Horsfall mucoprotein laden with necrotic tubular debris.
3. Emergency Indications for Renal Replacement Therapy (RRT)
In acute kidney injury, the decision to initiate emergency RRT (haemodialysis or continuous venovenous haemofiltration [CVVH]) is governed by the clinical and metabolic state rather than arbitrary creatinine numbers. The classical mnemonic is AEIOU :
A — Acidosis: Severe refractory metabolic acidaemia (pH < 7.20 or bicarbonate < 10–12 mmol/L) failing medical management (e.g. sodium bicarbonate infusion limited by volume overload or hypernatraemia).
E — Electrolytes: Life-threatening, refractory hyperkalaemia (K⁺ > 6.5 mmol/L) with ECG abnormalities (peaked T waves, broadened QRS, sine-wave pattern) unresponsive to insulin-dextrose, calcium gluconate, and potassium-wasting resins.
I — Ingestion (Dialysable Toxins): The "SLIME" toxins:
S alicylates (aspirin): Indicated for levels > 500 mg/L (> 3.6 mmol/L) or lower if severe pulmonary oedema, coma, or refractory acidosis exist.
L ithium: Indicated for acute intoxication > 4.0 mmol/L or chronic toxicity > 2.5 mmol/L with severe neurotoxicity (ataxia, seizures, delirium).
I sopropanol: Converted to acetone; causes ketosis without metabolic acidosis.
M ethanol: Toxic metabolite formic acid causes retinal damage and blindness; massive high anion gap metabolic acidosis.
E thylene Glycol: Toxic metabolite oxalic acid precipitates calcium oxalate crystals in tubules causing ATN, severe acidosis, and hypocalcaemia.
O — Overload: Refractory pulmonary oedema unresponsive to escalating high-dose intravenous loop diuretics (e.g. furosemide bolus/infusions).
U — Uraemic Complications:
Uraemic Pericarditis: Friction rub, pleuritic chest pain; high risk of haemorrhagic tamponade (anticoagulation and systemic thrombolysis strictly contraindicated; hemodialysis without heparin is the treatment of choice).
Uraemic Encephalopathy: Asterixis (flapping tremor), cognitive decline, seizures, coma.
Uraemic Bleeding: Qualitative platelet dysfunction driven by guanidinosuccinic acid and uraemic toxins disrupting glycoprotein Ib-IX and von Willebrand factor interaction. Managed acutely with desmopressin (DDAVP 0.3 μg/kg IV) , cryoprecipitate, and dialysis.
4. Chronic Kidney Disease: KDIGO Staging & Progression Retardants
Chronic kidney disease is defined by abnormalities of kidney structure or function persisting for > 3 months. KDIGO 2024 guidance mandates dual staging using eGFR (G category) and urinary albumin-to-creatinine ratio (ACR; A category) .
- eGFR Stage eGFR Range (mL/min/1.73 m²) Description
- G1 >= 90 Normal or high (requires structural/histological/albuminuria marker)
- G2 60–89 Mildly decreased (requires structural/urinary marker)
- G3a 45–59 Mildly to moderately decreased
- G3b 30–44 Moderately to severely decreased
- G4 15–29 Severely decreased (prepare for RRT / transplant access)
- G5 < 15 Kidney failure (end-stage renal disease, ESRD)
- Albuminuria Stage ACR Range (mg/mmol) ACR Range (mg/g) Category Description
- A1 < 3 < 30 Normal to mildly increased
- A2 3–30 30–300 Moderately increased (microalbuminuria)
- A3 > 30 > 300 Severely increased (macroalbuminuria / nephrotic range)
- Evidence-Based Renoprotection & Progression Retardants
Blood Pressure Targets: Under NICE NG203 guidelines, target systolic BP < 140/90 mmHg if ACR < 30 mg/mmol; tighten to < 130/80 mmHg if ACR >= 30 mg/mmol (or ACR >= 3 mg/mmol in diabetic kidney disease).
RAAS Inhibition: First-line therapy is an ACE inhibitor (e.g. ramipril) or ARB (e.g. losartan). They preferentially dilate efferent arterioles, reducing intraglomerular hypertension and slowing sclerosis. Monitoring: Check serum creatinine and potassium at 1–2 weeks. An increase in creatinine up to 30% (or drop in eGFR up to 25%) from baseline is physiologically expected and acceptable; discontinue only if the rise exceeds 30% or unmanageable hyperkalaemia occurs.
SGLT2 Inhibitors: Dapagliflozin and empagliflozin (DAPA-CKD, EMPA-KIDNEY) inhibit proximal tubular glucose/sodium co-transport, restoring tubuloglomerular feedback and reducing hyperfiltration. Recommended for adults with CKD (eGFR 20–45 mL/min or eGFR 45–90 with ACR >= 22.6 mg/mmol) regardless of diabetes status .
Non-Steroidal Mineralocorticoid Receptor Antagonist (Finerenone): Selectively blocks aldosterone-driven inflammation and fibrosis. Demonstrated in the FIDELIO-DKD and FIGARO-DKD trials to significantly reduce CKD progression and cardiovascular events in patients with type 2 diabetes and persistent albuminuria on maximum tolerated ACEi/ARB.
- 5. Systemic Complications: Anaemia of CKD & CKD-MBD
- Anaemia of Chronic Kidney Disease
Aetiology: Relative deficiency of renal erythropoietin (EPO) produced by peritubular capillary interstitial cells (fibroblasts) in the deep cortex and outer medulla. Compounded by elevated circulating hepcidin (decreased renal clearance and chronic microinflammation), which degrades ferroportin, trapping iron inside macrophages and hepatocytes and producing functional iron deficiency.
Morphology: Typically normochromic, normocytic anaemia with a low reticulocyte production index.
Therapeutic Algorithm:
Iron Repletion First: Prior to initiating erythropoiesis-stimulating agents (ESAs), optimize iron stores to ensure adequate substrate for erythropoiesis. Targets: serum ferritin > 100 µg/L (or > 200 µg/L in haemodialysis) and transferrin saturation (TSAT) > 20% . Intravenous iron (ferric carboxymaltose or ferric derisomaltose) is superior to oral iron in non-dialysis and dialysis CKD.
Erythropoiesis-Stimulating Agents (ESAs): Initiated if Hb < 100 g/L despite replete iron stores. Agents include recombinant human EPO (epoetin alfa/beta) or darbepoetin alfa.
Strict Target Haemoglobin: The target Hb is 100–115 g/L (never normalize Hb > 120–130 g/L). Landmark randomized controlled trials (CHOIR, CREATE, TREAT) demonstrated that targeting normal haemoglobin levels causes a statistically significant increase in stroke, deep vein thrombosis, cardiovascular death, and accelerated vascular access thrombosis.
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
CKD-MBD represents a systemic triad of biochemical abnormalities, bone disease (renal osteodystrophy), and vascular/valvular soft-tissue calcification. Reduced GFR --> Phosphate Retention (Hyperphosphataemia)
- |
- v
- Stimulation of Osteocytes --> Elevated FGF23 (with Klotho co-factor)
- |
- v
- Inhibition of Renal 1-alpha-hydroxylase (CYP27B1)
- |
- v
- Decreased Active 1,25-(OH)2 Vitamin D (Calcitriol)
- |
- v
- Decreased Intestinal Ca2+ Absorption --> Hypocalcaemia
- |
- v
- Parathyroid Gland Hyperplasia --> SECONDARY HYPERPARATHYROIDISM
- (High PTH, Low/Normal Ca2+, High PO43-)
Renal Osteodystrophy Spectrum:
Osteitis Fibrosa Cystica: High-turnover bone disease driven by excessive PTH; subperiosteal bone resorption, brown tumours (osteoclastomas), "rugger-jersey spine" on spinal radiography.
Osteomalacia: Defective bone mineralization due to severe calcitriol deficiency or historical aluminium binder toxicity.
Adynamic Bone Disease: Low-turnover bone disease caused by excessive suppression of PTH (iatrogenic overtreatment with active vitamin D analogues or calcium salts); prone to fracture and accelerated vascular calcification.
Tertiary Hyperparathyroidism: Following years of chronic end-stage kidney disease, prolonged parathyroid hyperplasia transitions to autonomous, monoclonal parathyroid adenomas that escape negative feedback. Characterized biochemically by markedly elevated PTH in the presence of HYPERCALCAEMIA and hyperphosphataemia.
Management Strategies:
Dietary Phosphate Restriction: First-line non-pharmacological step.
Phosphate Binders: Taken with meals. Non-calcium-based binders ( sevelamer carbonate , lanthanum carbonate) are strongly preferred over calcium-based binders (calcium acetate, calcium carbonate) in patients with hypercalcaemia or arterial calcification, as calcium-containing salts accelerate vascular stiffening and calciphylaxis.
Active Vitamin D Analogues: Oral alfacalcidol or calcitriol; directly suppress pre-pro-PTH gene transcription. Caution: can precipitate hypercalcaemia and hyperphosphataemia by enhancing intestinal absorption.
Calcimimetics (Cinacalcet): An allosteric activator of the calcium-sensing receptor (CaSR) on chief cells of the parathyroid gland. Increases receptor sensitivity to extracellular calcium, thereby suppressing PTH secretion without raising serum calcium or phosphate levels (in fact, it lowers both). Indicated for refractory secondary hyperparathyroidism or tertiary hyperparathyroidism awaiting parathyroidectomy.